Last updated: July 3, 2026
Litigation summary and analysis for In re Bendamustine Consolidated Cases II, No. 1:15-cv-00404
Executive summary: In re Bendamustine Consolidated Cases II (MDL-style consolidated case) under docket 1:15-cv-00404 consolidates patent litigation tied to bendamustine drug products. The record for this docket number, including parties, asserted patents, motion outcomes, claim-construction results, and final dispositions, is not available in the provided material. Without those case-specific facts, a complete and accurate litigation summary and merits analysis cannot be produced.
What happens in In re Bendamustine Consolidated Cases II (1:15-cv-00404)?
No case-specific outcomes, procedural posture, or substantive holdings can be stated for 1:15-cv-00404 because the underlying docket content (complaints, master complaint, assignments to specific plaintiffs/defendants, trial dates, or rulings) is not provided.
What procedural events matter most for bendamustine patent MDL cases?
A litigation summary typically hinges on:
- asserted patent list and priority
- claim construction rulings
- injunction or stay rulings
- settlement structures (license vs. “carve-out” timing)
- dismissal or summary judgment outcomes
- final judgment and appeal posture
Those specifics are not present.
Which patents were asserted in In re Bendamustine Consolidated Cases II (1:15-cv-00404)?
A patent-by-patent assertion map cannot be produced because the asserted patent numbers (and their corresponding claims and product mappings) are not included.
Which companies were litigants?
No party list (brand manufacturer, generic filers, ANDA sponsor defendants, or patent holders/assignees) is included for 1:15-cv-00404, so a reliable litigation participant analysis is not possible.
What jurisdiction and court handling occurred for 1:15-cv-00404?
The question requires confirmation of:
- presiding court/judge
- consolidation MDL origin and transfer history
- whether any matters were remanded for discovery or trial
Those facts are not provided.
How strong is the patent estate for bendamustine in this consolidated docket?
Strength analysis requires:
- which patents survived dispositive motions
- independent claim coverage breadth
- enforceability challenges (invalidity, §101, inequitable conduct where applicable)
- remaining injunction leverage
None of those outcomes or patent identities are available for 1:15-cv-00404.
What settlement outcomes occurred in In re Bendamustine Consolidated Cases II?
A settlement review needs:
- settlement date(s)
- settlement terms (license scope, supply/payment, launch dates)
- whether settlements were “no-authorization” type with carve-outs
- dismissal-with-prejudice details
No settlement terms or dates are provided for 1:15-cv-00404.
When did the case end for 1:15-cv-00404?
A timeline depends on:
- final judgment date
- voluntary dismissal date(s)
- final disposition order and docket entry references
- appellate history
No such disposition information is included.
What generic entry risks were addressed by the litigation?
This analysis requires knowing:
- whether the case involved ANDA patent certifications (Paragraph IV)
- whether any FDA approvals/launch dates were enjoined
- whether the court entered a 35 U.S.C. § 271(e)(4) injunction or limited relief
Those facts are not available.
How does In re Bendamustine Consolidated Cases II compare with other bendamustine consolidation dockets?
A comparison requires parallel dockets’ asserted patents, outcomes, and settlement terms. With only 1:15-cv-00404 and no case records, a valid comparative analysis cannot be prepared.
Key Takeaways
- No defensible docket-specific litigation summary can be produced for 1:15-cv-00404 without the asserted patents, litigants, and dispositive outcomes.
- No timeline, settlement analysis, or patent-strength assessment can be stated reliably because the underlying case record is not included.
FAQs
1) What is In re Bendamustine Consolidated Cases II (1:15-cv-00404)?
Not answerable with precision because docket-specific details are not provided.
2) Which bendamustine patents are involved in 1:15-cv-00404?
Not answerable because asserted patent identities are not provided.
3) Did the court issue claim construction or summary judgment rulings?
Not answerable because rulings are not provided.
4) Were any settlements reached in the consolidated case?
Not answerable because settlement terms or dates are not provided.
5) What is the likely impact on generic bendamustine launch timing?
Not answerable because injunction or stay outcomes are not provided.
References
No sources were cited because no case-specific record content was provided.
